Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He currently serves on the Board of Directors of Innate Immunotherapeutics and Avalia Immunotherapies and is a consultant for several other biotechnology companies. Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand. John Chiplin PhD NON-EXECUTIVE DIRECTOR John has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions in which John has been instrumental include Benitec BioPharma (US IPO), Medistem (acquired by Intrexon Corporation for US$26 million), former CEO of ASX-listed Arana Therapeutics (acquired by Cephalon Inc. for US$200 million), and Domantis (acquired by GSK for £230 million). Immediately prior to running Arana, John was head of the ITI Life Sciences investment fund in the UK, negotiating significant funding with Government Ministers. His own investment company, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. John’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on the boards of Batu Biologics, Benitec BioPharma (NASDAQ:BNTC), The Coma Research Institute, Cynata Therapeutics (ASX:CYN), Prophecy Inc, Scancell Holdings plc (LSE:SCLP), and ScienceMedia Inc.  

 Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He currently serves on the Board of Directors of Innate Immunotherapeutics and Avalia Immunotherapies and is a consultant for several other biotechnology companies. Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand.